How big is Keros Therapeutics, Inc.?

As of Jun 18, Keros Therapeutics, Inc. has a market capitalization of 546.68 million, with net sales of 214.72 million and a net profit of 4.20 million over the latest four quarters. The company reported shareholder's funds of 571.55 million and total assets of 615.89 million as of Dec 24.

Market Cap: As of Jun 18, Keros Therapeutics, Inc. has a market capitalization of 546.68 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Keros Therapeutics, Inc. reported net sales of 214.72 million and a net profit of 4.20 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 571.55 million and total assets of 615.89 million.

What does Keros Therapeutics, Inc. do?

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. As of March 2025, it reported net sales of $211 million and a market cap of $546.68 million.

Overview: <BR>Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, operating within the Pharmaceuticals & Biotechnology industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 211 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 148 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 546.68 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 145.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: 0.58% <BR>Price to Book: 0.75<BR><BR>Contact Details: <BR>Address: 99 Hayden Ave Ste 120 (Bld E, LEXINGTON MA : 02421 <BR>Tel: ['1 617 5138774', '1 646 3782936'] <BR>Website: https://www.kerostx.com/

Should I buy, sell or hold Keros Therapeutics, Inc.?

Who are in the management team of Keros Therapeutics, Inc.?

As of March 2022, Keros Therapeutics, Inc.'s management team includes Dr. Jasbir Seehra as CEO and Director, along with Independent Directors Dr. Mary Gray, Mr. Nima Farzan, Mr. Carl Gordon, Mr. Tomer Kariv, and Mr. Julius Knowles.

As of March 2022, the management team of Keros Therapeutics, Inc. includes Dr. Jasbir Seehra, who serves as the Chief Executive Officer and Director. Additionally, the Board of Directors comprises Dr. Mary Gray, Mr. Nima Farzan, Mr. Carl Gordon, Mr. Tomer Kariv, and Mr. Julius Knowles, all of whom hold the designation of Independent Director.

Is Keros Therapeutics, Inc. technically bullish or bearish?

As of August 13, 2025, Keros Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but significantly underperformed over the past year.

As of 13 August 2025, the technical trend for Keros Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The Bollinger Bands indicate a bullish stance on the weekly chart but are mildly bearish on the monthly. Moving averages are showing a mildly bearish trend on the daily timeframe. The KST and Dow Theory both suggest a mildly bullish outlook on the weekly and monthly charts, while the OBV is also mildly bullish across both timeframes.<BR><BR>In terms of performance, Keros Therapeutics has outperformed the S&P 500 over the past week and month, with returns of 1.78% and 10.47% respectively, compared to the S&P 500's 1.05% and 2.33%. However, the longer-term returns are significantly negative, with a 1-year return of -71.21% versus the S&P 500's 17.14%, indicating substantial underperformance over that period. Overall, the current technical stance is mildly bearish, reflecting mixed signals across various indicators.

Is Keros Therapeutics, Inc. overvalued or undervalued?

As of October 17, 2025, Keros Therapeutics, Inc. is considered fairly valued despite a high P/E ratio of 145 and a PEG ratio of 1.42, indicating potential overvaluation, especially as it has underperformed the S&P 500 with a 1-year return of -77.36%.

As of 17 October 2025, the valuation grade for Keros Therapeutics, Inc. has moved from very attractive to fair. The company appears to be overvalued given its high P/E ratio of 145, which significantly exceeds the industry average, and a PEG ratio of 1.42, indicating that growth expectations may not justify the current price. Additionally, the Price to Book Value stands at 0.84, suggesting that the stock is trading below its book value, which could be a potential red flag.<BR><BR>In comparison to peers, Keros Therapeutics has a P/E of 33.47, while Day One Biopharmaceuticals, Inc. and Revance Therapeutics, Inc. are both classified as risky with negative P/E ratios, indicating a challenging environment for the sector. Notably, Keros has underperformed against the S&P 500, with a 1-year return of -77.36% compared to the index's 14.08%, reinforcing concerns about its current valuation.